Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm - LARVOL DELTA

Vitamin D Level and Antibody Response to the BBIBP-CorV Vaccine in Pregnant Women. (PubMed, J Trop Med) - "Our study showed that two doses of the BBIBP-CorV vaccine elicited antibody responses against COVID-19 in only a small proportion of pregnant women, suggesting that higher doses or alternative vaccine platforms may be required to protect pregnant women. Despite the existence of a relationship between vitamin D levels and antibody response in our study, prospective clinical trial studies are needed to draw definitive conclusions regarding the effect of vitamin D on antibody response."

Journal • Infectious Disease • Novel Coronavirus Disease

Safety and antibody responses to inactivated COVID-19 vaccines among elderly patients with COPD: a prospective cohort study. (PubMed, Front Immunol) - "We aimed to assess the safety and longitudinal antibody dynamics of a three-dose schedule of the inactivated COVID-19 vaccine (Vero cell, Covilo) in elderly patients with COPD...A three-dose regimen of Covilo is safe and effectively elicits antibody responses in elderly COPD patients. However, the rapid waning of antibody levels suggests a need for optimized booster strategies to maintain long-term protection in this vulnerable group."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Long-term cross-variant Fc-mediated immune responses against SARS-CoV-2 induced by a heterologous adenoviral/inactivated virus prime-boost vaccination strategy. (PubMed, NPJ Vaccines) - "We evaluated the immunogenicity and longevity of four vaccine regimens in adults from Mozambique and Madagascar: single-dose Ad26.COV2.S (Ad26.S), homologous BBIBP-CorV (BBIBP), and two heterologous combinations (BBIBP-Ad26.S and Ad26.S-BBIBP, in prime-boost order). Compared to the other regimens, antibody-dependent natural killer cell activation (ADNKA) emerged as a distinct characteristic of durable cross-variant immunity in Ad26.S-BBIBP recipients. These findings highlight that the Ad26.S-BBIBP regimen is immunologically advantageous, with Fc-mediated effector functions, particularly ADNKA, representing an important characteristic of its relatively durable and cross-strain protection even as neutralizing antibody titers decline."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, immunogenicity, and long COVID outcomes following inactivated COVID-19 vaccine boosters in elderly Chinese: a prospective cohort study. (PubMed, Front Immunol) - "A third booster of inactivated SARS-CoV-2 vaccine administered within 2-6 months of the second dose is safe and significantly boosts humoral immunity in adults ≥60 years. The three-dose Covilo regimen and a 6-month dosing interval optimized immunogenicity and were associated with the lowest risks of COVID-19 symptoms and long COVID, highlighting the importance of vaccine-specific and interval-adjusted booster strategies for older populations."

Clinical • Journal • Fatigue • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults. (PubMed, Front Immunol) - "A total of 601 participants, primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac, were randomized (1:1) to receive 15 μg (fractional dose) or 30 μg (standard dose) of BNT162b2...For memory T-cell ICS responses, durability was maintained over 12 months post-vaccination for both wild-type and JN.1 responses. Overall, fractional booster dosing produced comparable and robust long-term humoral and cellular immune responses to a standard dose, including against the JN.1 variant."

Clinical • IO biomarker • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD69 • IFNG • IL2 • TNFA • TNFRSF9

Humoral immunity and infection status of PLWH following vaccination after the BA.5/BF.7 wave. (PubMed, Front Microbiol) - "This study enrolled 232 PLWH who had received either the CoronaVac/BBIBP-CorV or ZF2001 vaccine and experienced the BA.5/BF.7 wave in China between January and April 2023...However, this hybrid immunity offers limited protection against Omicron variant XBB.1.5. Regular monitoring of immune responses to new vaccines targeting emerging variants is crucial for optimizing COVID-19 prevention strategies in PLWH."

Journal • Fatigue • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases • CD4

Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial. (PubMed, Front Immunol) - P3 | "In this randomised, controlled trial, adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were assigned (1:1) to 15 μg or 30 μg BNT162b2...Equivalent immunity and safety from 15 μg and 30 μg BNT162b2 boosters support fractional dosing as a cost-saving strategy. https://clinicaltrials.gov/study/NCT05265065, identifier NCT05265065."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Immune Response to COVID-19 Vaccines: Updates in a Fast-Moving Scenario. (PubMed, Vaccines (Basel)) - "Far from being complete and exhaustive, this Special Issue provides the reader with fresh insights into several critical questions raised by or connected to the advent of COVID-19 vaccines. This introductory article provides an overview of their contribution, while offering a quick glance at the current state of the art."

Journal • Cardiovascular • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Rheumatology • Transplantation

Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (clinicaltrials.gov) - P2 | N=1919 | Completed | Sponsor: Victoria Biomedical Research Institute

New P2 trial • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4

Effectiveness of COVID-19 Vaccination in Reducing Severity Among SARS-CoV-2 Infected Patients: A Prospective Study From Iraq. (PubMed, Health Sci Rep) - "The type of vaccination was significantly correlated with disease severity (p < 0.001), with more severe or critical symptoms reported in patients vaccinated with BBIBP-CorV compared to those vaccinated with BNT162b2 or ChAdOx1 nCoV-19 (AZD1222). COVID-19 vaccination, while not preventing infection, markedly reduced disease severity and mortality-especially with full dosing and among high-risk groups. The differential effectiveness observed among vaccine types highlights the importance of optimizing vaccine strategies based on real-world outcomes, particularly in resource-constrained settings like Iraq."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Temporal dynamics of SARS-CoV-2 antibodies and IgG subclasses following multiple doses and diverse COVID-19 vaccine combinations. (PubMed, Front Immunol) - "The present study investigated the humoral immune response in 331 participants between January 2021 and January 2023, who received mRNA (BNT162b2-BioNTech/Pfizer, mRNA-1273-Moderna), vector-based (ChAdOx1-S-AstraZeneca, Gam-COVID-Vac-Gamaleya Research Institute), inactivated virus (BBIBP-CorV-Sinopharm) vaccines, or a heterologous combination (ChAdOx1-S followed by mRNA), with all participants receiving an mRNA booster 6-8 months after primary vaccination. The IgG subclass response was more influenced by the type of vaccine used for the two-dose primary vaccination than by the mRNA vaccine used for boosting. Altogether, these findings underscore the importance of booster doses and provide valuable insight into the longevity and quality of humoral responses, including the durability and breadth of neutralizing antibodies, across different vaccination strategies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance Center. (PubMed, Vaccine) - "This first post-marketing safety evaluation of BBIBP-CorV among Peruvian healthcare personnel found a low AEFI reporting rate, with mostly mild events. Access to medical records enabled accurate assessment, supporting local pharmacovigilance and public health decision-making."

Adverse events • Journal • P4 data • Retrospective data • Infectious Disease • Novel Coronavirus Disease • Ophthalmology • Respiratory Diseases

Safety of the BBIBP-CorV COVID-19 Vaccine in Relation to Adverse Clinical Outcomes in Newborns: A Prospective Cohort Study. (PubMed, Int J Womens Health) - "Clinically, these findings suggest that obstetricians should recommend COVID-19 vaccination during preconception counselling as a protective measure for future pregnancies. Public health implications include (1) supporting the integration of inactivated vaccines into prepregnancy health care programs to enhance immunity before gestation and (2) informing national policies to accelerate vaccine coverage among women of childbearing age, thereby reducing maternal-foetal risks in potential pandemics."

Adverse events • Clinical data • Journal • Infectious Disease • Novel Coronavirus Disease • Obstetrics • Respiratory Diseases

Retrospective Cohort Analysis of Survival After SARS-CoV-2 Infection by Vaccination Status in Jamaica, April-December 2021. (PubMed, Vaccines (Basel)) - "COVID-19 vaccines were effective in preventing COVID-19 death in a population with low vaccination coverage. Limitations of the analysis include the use of surveillance data (under-reporting of cases, missing data), exclusion of partially vaccinated cases, and insufficient data on important confounders (circulating variants and comorbidities)."

Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Single-cell transcriptome profile during the antibody decline phase following inactivated COVID-19 vaccination. (PubMed, Front Cell Infect Microbiol) - "Sixty-five healthy volunteers received two doses of BBIBP-CorV...Cell-cell communication analysis further identified enhanced MHC-I signaling in high-titer groups, dominated by HLA-B interactions with CD8+ T cells. These findings reveal a state of balanced immune alertness during the decline phase, providing insights into the cellular and molecular determinants of long-term humoral immunity and informing future vaccine design."

Journal • Infectious Disease • Novel Coronavirus Disease • CD8 • HLA-B

Impact of COVID-19 and Vaccination on Lower Urinary Tract Symptoms: Insights From a Prospective Cohort Study. (PubMed, Neurourol Urodyn) - "LUTS are prevalent in the acute phase of COVID-19, especially among women, but tend to improve within 3 months. Unexpectedly, full vaccination-especially with inactivated virus vaccines-was associated with increased odds of moderate to severe LUTS during hospitalization. Further studies are warranted to explore the underlying mechanisms and long-term implications."

Journal • Critical care • Infectious Disease • Novel Coronavirus Disease • Overactive Bladder • Respiratory Diseases • Urinary Incontinence • Urology

Safety of sinopharm COVID-19 vaccine in children and adolescents aged 5 to 18 years: a cohort event monitoring study. (PubMed, BMC Public Health) - "Sinopharm is a safe and well-tolerated vaccine option for children and adolescents and can be recommended for this population."

Journal • CNS Disorders • Epilepsy • Fatigue • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Pain

Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial. (PubMed, Vaccine) - P3 | "15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Manufacturing Technology and Effectiveness of Corona Vaccines: A Bibliometric Review. (PubMed, Arch Razi Inst) - "Furthermore, elasomeran, covilo, and tozinameran emerged as more recent than other keywords based on their temporal distribution. This study examines the documents published in one of the most reliable databases of vaccines against the novel strain of severe acute respiratory syndrome (SARS-CoV-2) from a bibliometric perspective. The findings of this study are expected to provide valuable insights and direction for future research initiatives, opportunities, and challenges in this field."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Serological Studies of IgG and IgM in Response to SARS-CoV-2 Vaccination in Erbil, Kurdistan-Iraq. (PubMed, Arch Razi Inst) - "The present study aims to provide a comparative analysis of the humoral immune responses elicited by BNT162b2 (mRNA-based), BBIBP-CorV (inactivated virus), and ChAdOx1 (dsDNA-recombinant) vaccines against the SARS-CoV-2 virus. The enhanced immune response observed with Sinopharm could be attributed to its nature as an inactivated subunit vaccine. The immunological reactions to the vaccines studied in the following studies have prompted a lot of issues about how they happen, and the study recommends more studies regarding the most effective vaccines among the Kurdish people in the Kurdistan Region of Iraq."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Impact of obstructive sleep apnea severity and treatment on COVID-19 vaccine-induced immune responses. (PubMed, J Thorac Dis) - "This study examines the effects of OSA on immune responses following the third dose of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac or BBIBP-CorV)...These findings highlight a severity-dependent impairment of vaccine-induced immune responses in untreated OSA participants, with evidence that PAP treatment may enhance vaccine efficacy. This study emphasizes the need to consider OSA severity and treatment when optimizing vaccination strategies for this population."

Journal • Infectious Disease • Novel Coronavirus Disease • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Seroprevalence and persistence of humoral immunity in response to SARS-CoV-2 vaccination and mild infection in Morocco: a cross-sectional study. (PubMed, Pan Afr Med J) - "This study evaluated the humoral immune response to the BBIBP-CorV and ChAdOx1 nCoV-19 vaccines in healthy donors with varying doses and infection histories. hybrid immunity, involving prior infection and full vaccination, offers enhanced and longer-lasting protection. These results support the need for targeted vaccination strategies to optimize immunity and reduce the risk of adverse outcomes, especially in high-risk populations."

Journal • Observational data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

False positive results in the Widal test in adults immunized with the Commirnaty (Pfizer-BioNtech) and BBIBP-CorV (Sinopharm) vaccines against COVID-19. (PubMed, Front Med (Lausanne)) - "Our results suggest misleading results of the Widal test in patients vaccinated against COVID-19, mainly in those vaccinated with Commirnaty. It is important to monitor and evaluate the results of routine immunological tests to ensure the quality of medical care."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique. (PubMed, Clin Infect Dis) - P2 | "The noninferiority criterion was met only in arm A1 versus A2. HePB regimens were safe and well tolerated."

Clinical • Head-to-Head • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial. (PubMed, EClinicalMedicine) - P3 | "This Phase 3, multicenter, international, randomized, active-controlled trial compared UB-612 as a third-dose heterologous booster to BNT162b2, ChAdOx1-S, or BBIBP-CorV homologous boosters in healthy subjects aged ≥16 years. In a pivotal Phase 3 study, UB-612 demonstrated the potential for broad use as a cross-platform heterologous booster, restoring protective immunity in adults previously vaccinated with mRNA, adenovirus-vectored, or inactivated virus-based COVID-19 vaccines. The study was co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity."

Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases